Efficacy and Safety Analysis of ICIs Plus Angiogenesis Inhibitors for Treatment of Advanced NSCLC in Elderly Patients

NCT05688046 · clinicaltrials.gov ↗

COMPLETED

Status

79

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Immune checkpoint inhibitors plus angiogenesis inhibitors
DRUG: Immune checkpoint inhibitors without angiogenesis inhibitors

Sponsor

Suzhou Municipal Hospital